Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study

期刊论文
出版模式：

开放获取
发表日期：

2024年10月28日

查看全文

Bjørk K. Sofíudóttir,
Heidi L. Munk,
Robin Christensen,
Sören Möller,
Silja H. Overgaard,
Grith L. Sorensen,
Karen M. Møllegaard,
Jessica Pingel,
Anders B. Nexøe,
Henning Glerup,
Tanja Guldmann,
Natalia Pedersen,
Jens Frederik Dahlerup,
Christian L. Hvas,
Karina W. Andersen,
Mohamad Jawhara,
Ole Haagen Nielsen,
Fredrik Olof Bergenheim,
Anette Bygum,
Jesper R. Davidsen,
Signe Bek Sørensen,
Jacob B. Brodersen,
Jens Kjeldsen,
Vibeke Andersen,
Torkell Ellingsen

摘要

Background

Currently, there are no reliable biomarkers for predicting treatment response in chronic inflammatory diseases (CIDs).

Objective

To determine whether serum microfibrillar-associated protein 4 (MFAP4) levels can predict the treatment response to biological therapy in patients with CIDs.

Methods

The BELIEVE study was originally designed as a prospective, multi-center cohort study of 233 patients with either rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, Crohn’s disease, or ulcerative colitis, initiating treatment with a biologic agent (or switching to another). Clinical assessment and blood sample collection were performed at baseline and 14–16 weeks after treatment initiation. The primary analyses included participants with available blood samples at baseline; missing data were handled as non-responders. The patients were stratified into the upper tertile of serum MFAP4 (High MFAP4) versus a combined category of middle and lower tertiles (Other MFAP4). The primary outcome was the proportion of patients with clinical response to biologic therapy after 14–16 weeks.

Results

211 patients were included in the primary analysis population. The mean age was 43.7 (SD: 14.8) years, and 120 (59%) were female. Positive treatment response was observed in 41 (59%) and 69 (49%) for High MFAP4 and Other MFAP4, respectively. When adjusting for pre-specified variables (CID, age, sex, smoking status, and BMI), the adjusted OR was 2.28 (95% CI: 1.07 to 4.85) for a positive treatment outcome in the High MFAP4 group.

Conclusion

A high MFAP4 status before initiating biological treatment is associated with a positive clinical response, when adjusting for confounding factors.